公开(公告)号：US12012456B2

公开(公告)日：2024-06-18

申请号：US17772350

申请日：2020-07-31

申请人： SHANGHAI NOVAMAB BIOPHARMACEUTICALS CO., LTD.

发明人： Yakun Wan ,  Min Zhu ,  Junwei Gai ,  Xiaoning Shen

IPC分类号： C07K16/28 ,  A61K47/68 ,  C12N15/85

CPC分类号： C07K16/2866 ,  A61K47/6849 ,  C12N15/85 ,  C07K2317/24 ,  C07K2317/35 ,  C07K2317/569 ,  C07K2319/30 ,  C12N2800/107

摘要： Disclosed is an anti-IL-4R single-domain antibody and the use thereof. In particular, disclosed are a IL-4R single-domain antibody and a VHH chain thereof, a coding sequence encoding the above-mentioned single-domain antibody or the VHH chain thereof, a corresponding expression vector, host cells capable of expressing the single-domain antibody, and a method for producing the single-domain antibody. The single-domain antibody can specifically recognize human and marmoset IL-4R, but does not recognize mouse IL-4R, and the specificity is good; the single-domain antibody can effectively inhibit the proliferation of TF-1 cells and the activation of a pSTAT6 signaling pathway in cells.

公开(公告)号：US11427635B2

公开(公告)日：2022-08-30

申请号：US16763052

申请日：2018-11-16

申请人： SHANGHAI NOVAMAB BIOPHARMACEUTICALS CO., LTD.

发明人： Yakun Wan ,  Xiaoning Shen ,  Min Zhu

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K39/00

摘要： A CD47 single-domain antibody and use thereof, and in particularly, a blocking type single-domain antibody for integrin-related protein (CD47) and derivative proteins thereof. In particular, disclosed are an integrin-related protein (CD47) binding molecule and use thereof, particularly in the treatment and/or prevention, or diagnosis of CD47-associated diseases, such as tumors. The CD47 single-domain antibody involved can effectively block the interaction between CD47 and a ligand SIRPa thereof, has good binding activity, blocking activity, affinity and stability, can effectively enhance the phagocytosis of tumor cells by macrophages, and shows significant anti-tumor activity in both a human lymphoma model and a human ovarian cancer model. In addition, the antibody does not cause hemoagglutination in vitro, and shows excellent safety in cynomolgus monkeys.

公开(公告)号：US11912770B2

公开(公告)日：2024-02-27

申请号：US16970083

申请日：2019-02-14

申请人： SHANGHAI NOVAMAB BIOPHARMACEUTICALS CO., LTD.

发明人： Yakun Wan ,  Min Zhu ,  Xiaoning Shen ,  Junwei Gai

IPC分类号： C07K16/28 ,  A61K39/00

CPC分类号： C07K16/2827 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/35 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： Provided are a single-domain antibody against human programmed death-ligand 1 (PD-L1) and application thereof. The PD-L1 binding molecule of the present invention can be used for treating and/or preventing, or diagnosing PD-L1 related diseases such as tumors.